Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL-NK-PDAC in advanced pancreatic ductal adenocarcinoma
NCT07627711Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of EB-DNK101 and EB-DNK102 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Biotech Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 12 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
EB-DNK101EB-DNK102
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07627711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627711.